Biodesix expects $101M-$103M 2026 revenue while planning to exit 2026 with ~115 sales reps (NASDAQ:BDSX)

Biodesix reported 10% revenue growth in Q3 2026, with diagnostic testing revenue up 16% and test volumes increasing 24%. The company maintains a gross margin of 81%. Management expects 2026 revenue to be $101M-$103M and plans to have around 115 sales reps by year-end, according to CEO Scott Hutton.

Original reporting
Published Nov 6, 2026, 8:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BDSX
Bullish
high confidence
Mentioned
$BDSX
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BDSXBullishMed
01

Why it matters

Earnings beat may trigger short‑term price rally and attract new institutional interest.

02

Market read

First‑time disclosure of Q3 performance provides fresh data for traders.

03

What to watch

Potential regulatory or reimbursement risks not addressed in the call.

Relevance 6/10Novelty 6/10Timing: after‑hours earnings call

Background

Biodesix is a molecular diagnostics company focused on lung disease testing.

Company-level read

Ticker impact

$BDSXBullishHigh confidence
Context

Biodesix reported Q3 revenue up 10% and diagnostic testing revenue up 16% with gross margin at 81% during its earnings call.

Expected impact

likely upward pressure as investors price in better‑than‑expected growth

Evidence & confidence

Revenue and margin beats signal improved demand for diagnostics, supporting a bullish bias.

Market effects

Positive earnings may lift other diagnostic and biotech peers.

Limited to US biotech sector.

Modest; primarily affects niche diagnostic market.

Counterpoint

If growth slows in upcoming quarters, current optimism could be premature.

Key entities

  • Scott Hutton

    President, CEO & Director of Biodesix who delivered the earnings commentary.

Related articles

High

Biodesix Q3FY26 Results: Revenue misses estimates, stock falls 29%

Biodesix Inc reported Q3FY26 revenue of $24.0M, missing estimates of $27.44M. Shares fell 29.44% after-hours. Full-year guidance was reduced to $101M-$103M from $108M-$114M. Revenue growth was 10% YoY, but test volume growth was offset by lower revenue per test. Gross margin remained at 81%, and net loss improved 8% YoY to $8.0M.

$BDSXMed

Biodesix Announces Third Quarter 2026 Results and Highlights

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Third Quarter 2026 Results and Highlights Delivered total revenue of $24.0 million, an increase of 10% year over year Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24% Maintained an 81% gross margin, improved Net

$BDSXMedAI 8/10

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.

$BDSXHigh

Biodesix Announces Second Quarter 2026 Results and Highlights

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere